This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rudolph, P. Articles by Schmidt, D. Search for Related Content PubMed PubMed Citation Articles by Rudolph, P. Articles by Schmidt, D.

American Journal of Pathology, Vol 150, 133-145, Copyright © 1997 by American Society for Investigative Pathology

REGULAR ARTICLES

Prognostic significance of the proliferative activity in neuroblastoma

P Rudolph, T Lappe, B Hero, F Berthold, R Parwaresch, D Harms and D Schmidt
Department of General Pathology, University of Kiel, Germany.

The prognostic significance of the immunohistochemically assessed growth fraction in neuroblastomas was determined in relation to tumor grade and tumor stage. A total of 101 cases of neuroblastoma were examined with the monoclonal antibodies PC10 against proliferating cell nuclear antigen (PCNA) and Ki-S5 against the Ki-67 protein. Patients were followed for a mean time of 4.8 years. Expression of both PC10 and Ki-S5 was found to be significantly linked to tumor grade and tumor stage. Prognostically favorable stage IVs was associated with low PCNA and Ki-S5 levels. For ganglioneuroblastoma, significant differences were found between the diffuse and the composite type. In univariate analysis of stage III and IV tumors, Ki-S5 and PCNA scores were significantly correlated with disease-free survival (P < 0.0015), allowing definition of a subset of cases with favorable outcome. As to Shimada's group with poor prognosis, significant differences in the clinical course were found for low and high Ki-S5 scores (P = 0.036) but not for PCNA. In multivariate analysis, only patient age, Shimada's grade, and Ki-S5 scores achieved prognostic significance. We conclude that proliferation marker Ki-S5 may provide substantial prognostic information and might become a useful adjunct for predicting the clinical courses of neuroblastoma.

This article has been cited by other articles:

				M. Krams, H.-J. Heidebrecht, B. Hero, F. Berthold, D. Harms, R. Parwaresch, and P. Rudolph repp86 Expression and Outcome in Patients With Neuroblastoma J. Clin. Oncol., May 1, 2003; 21(9): 1810 - 1818. [Abstract] [Full Text] [PDF]

				M. Krams, A. Claviez, K. Heidorn, G. Krupp, R. Parwaresch, D. Harms, and P. Rudolph Regulation of Telomerase Activity by Alternate Splicing of Human Telomerase Reverse Transcriptase mRNA in a Subset of Neuroblastomas Am. J. Pathol., November 1, 2001; 159(5): 1925 - 1932. [Abstract] [Full Text] [PDF]

				P. Rudolph, P. Alm, H.-J. Heidebrecht, H. Bolte, V. Ratjen, B. Baldetorp, M. Ferno, H. Olsson, and R. Parwaresch Immunologic Proliferation Marker Ki-S2 as Prognostic Indicator for Lymph Node-Negative Breast Cancer J Natl Cancer Inst, February 3, 1999; 91(3): 271 - 278. [Abstract] [Full Text] [PDF]